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Abstract
Background: Altered expression of mRNA splicing factors occurs with ageing in vivo and is thought to be an
ageing mechanism. The accumulation of senescent cells also occurs in vivo with advancing age and causes much
degenerative age-related pathology. However, the relationship between these two processes is opaque.
Accordingly we developed a novel panel of small molecules based on resveratrol, previously suggested to alter
mRNA splicing, to determine whether altered splicing factor expression had potential to influence features of
replicative senescence.
Results: Treatment with resveralogues was associated with altered splicing factor expression and rescue of multiple
features of senescence. This rescue was independent of cell cycle traverse and also independent of SIRT1, SASP
modulation or senolysis. Under growth permissive conditions, cells demonstrating restored splicing factor
expression also demonstrated increased telomere length, re-entered cell cycle and resumed proliferation. These
phenomena were also influenced by ERK antagonists and agonists.
Conclusions: This is the first demonstration that moderation of splicing factor levels is associated with reversal of
cellular senescence in human primary fibroblasts. Small molecule modulators of such targets may therefore
represent promising novel anti-degenerative therapies.
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Background
Messenger RNA (mRNA) processing has been implicated
as a key determinant of lifespan. Splicing factor expression
is dysregulated in the peripheral blood of aging humans,
where they are the major functional gene ontology class
whose transcript patterns alter with advancing age [1] and
in senescent primary human cells of multiple lineages [2].
Splicing factor expression is also an early determinant of
longevity in mouse and man [3], and in both species these
changes are likely to be functional, since they are associated
with alterations in splice site usage for many genes [1–3].
Recent data suggests that modification of the levels of SFA-
1, a core component of the spliceosome, influences lifespan
in C. elegans through interaction with TORC1 machinery
[4]. Diseases for which age is a significant risk factor includ-
ing Alzheimer’s disease [5], Parkinson’s disease [6] and can-
cer [7] are also marked by major changes in the isoform
repertoires, highlighting the importance of correct splicing
for health throughout the life course. Thus, the loss of fine-
tuning of gene expression in ageing tissues and the result-
ing failure to respond appropriately to intrinsic and extrin-
sic cellular stressors has the potential to be a major
contributor to the increased physiological frailty seen in
aging organisms [8].
The splicing process is regulated on two levels. Firstly,
constitutive splicing is carried out by the core spliceosome,
which recognises splice donor and acceptor sites that define
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introns and exons. However, fine control of splice site usage
is orchestrated by a complex interplay between splicing
regulator proteins such as the Serine Arginine (SR) class of
splicing activators and the heterogeneous ribonucleoprotein
(hnRNP) class of splicing repressors. Splicing activators
bind to exon and intron splicing enhancers (ESE, ISE), and
splicing inhibitors to intron and exon splicing silencers
(ESS, ISS). Splice site usage relies on the balance between
these factors and occurs in a concentration-dependent
manner [9–11]. Other aspects of information transfer from
DNA to protein, such as RNA export and mRNA stability
are also influenced by splicing factors [12]. Intriguingly, in
addition to their splicing roles, many splicing factors have
non-canonical additional functions regulating processes
relevant to ageing. For example, hnRNPK, hnRNPD and
hnRNPA1 have been shown to have roles in telomere
maintenance [13–15], hnRNPA1 regulates the stability of
SIRT1 mRNA transcripts [16] and hnRNPA2/B1 is involved
in maintenance of stem cell populations [17]. Splicing fac-
tor expression is known to be dysregulated in senescent
cells of multiple lineages [2] and it is now well established
that the accumulation of senescent cells is a direct cause of
multiple aspects of both ageing and age-related disease in
mammals [18].
Senescent cells accumulate progressively through life in a
variety of mammalian species [15], and premature senes-
cence is a hallmark of many human progeroid syndromes.
Conversely, dietary restriction, which increases longevity, re-
tards the accumulation of senescent cells. Most compel-
lingly, deletion of senescent cells in transgenic mice
improves multiple aspects of later life health and extends
lifespan [19]. The mechanisms by which senescent cells me-
diate these deleterious effects are complex but include fac-
tors such as ectopic calcification in the case of vascular
smooth muscle cells [20] and secretion of pro-inflammatory
cytokines, the well-known Senescence Associated Secretory
Phenotype (SASP) [21]. These observations suggest that an
interrelationship may exist between well characterised
mechanisms of ageing, such as cellular senescence, and the
RNA splicing machinery where the mechanistic relationship
to ageing remains largely correlational.
In contrast to the situation with core spliceosomal pro-
teins such as SFA-1, perturbation of a single splicing regula-
tor by standard molecular techniques such as knockdown
or overexpression is unlikely to be informative for assess-
ment of effects on ageing and cell senescence, since ageing
is characterised by co-ordinate dysregulation of large mod-
ules of splicing factors [1, 2]. Splice site choice is also
dependent on the balance between more than a hundred
splicing activator and splicing inhibitor regulatory proteins,
which differ from splice site to splice site and from tissue to
tissue [9, 10]. Thus experimental tools capable of co-
ordinately modulating the expression of multiple compo-
nents simultaneously are required to address the potential
effects of the dysregulation of large numbers of splicing fac-
tors that we note during the ageing process. Small mole-
cules such as resveratrol have been reported to influence
splicing regulatory factor expression in transformed cell
lines such as HEK293 and HeLa [22], although it is not yet
known whether this is a direct or indirect effect. Unfortu-
nately, resveratrol has multiple biological effects, including
a reduction of pro-inflammatory cytokine expression [23]
as well as its canonical activity against SIRT1 [24] thus a
‘clean’ assessment of the effects of moderation of splicing
factor levels on cell physiology cannot be achieved using
this compound alone.
We have overcome this limitation through develop-
ment of a novel library of resveratrol-related compounds
(resveralogues) which are all capable of either directly or
indirectly influencing the expression of multiple splicing
factors of both SRSF and HNRNP subtypes, whilst exhi-
biting differential activity against SIRT1 and SASP.
Treatment of senescent human fibroblasts from different
developmental lineages with any of these novel mole-
cules shifts expression patterns of multiple splicing fac-
tors to those characteristic of much earlier passage cells.
This change occurs regardless of cell cycle traverse and
is associated with a marked decrease in key biochemical
and molecular biomarkers of senescence without any
significant alteration in levels of apoptosis. Elevated spli-
cing factor expression is also associated with elongation
of telomeres, and in growth permissive conditions, these
previously senescent populations show significant in-
creases in growth fraction (as measured by Ki67 stain-
ing) and in absolute cell number, indicating cell cycle re-
entry. The mechanisms by which ‘rejuvenation’ occurs
are independent both of SIRT1 activation, or effects on
the SASP. Thus, molecules that modulate RNA splicing
patterns, either directly or indirectly, may have the po-
tential to delay or reverse cellular senescence with con-
sequent positive impact on human health span.
Results
Synthesis of novel resveralogues
Resveratrol (RSV) has been reported to extend lifespan
in various model organisms through activation of the
NAD-dependent protein deacetylase, SIRT1 [24], while
replenishment of NAD+ improves lifespan and health
span in ATM− worms and mice [25]. We therefore set
out to rationally design a panel of novel resveratrol-like
compounds (Fig. 1a) with the goal of identifying com-
pounds that could restore splicing factor expression to
levels comparable with those seen in young cells, but
with differing effects on SIRT1 activation and the
senescence-associated secretory phenotype (SASP) to
allow assessment of molecular mechanism. Synthesis of
the backbone was achieved as previously reported [26],
with additional functionality and diversity achieved via
Latorre et al. BMC Cell Biology  (2017) 18:31 Page 2 of 15
functional group interconversion (Fig. 1b). Compounds
were chosen for further analysis based on (i) structural
novelty and low cytotoxicity (ii) differential SIRT1 acti-
vation activity (iii) differential effects on the suppression
of SASP components and (iv) previously observed in-
creases in the Ki67 positive fraction of MRC5 cultures at
5 μM. We also included the parent compound (resvera-
trol) and a major metabolite (dihydroresveratrol).
Fig. 1 Synthesis and characterisation of novel resveralogues. a Structures of resveralogues 1–6. Compounds are: 1 resveratrol, 2 resveratrol’s primary
metabolite, dihydroresveratrol, 3 (E)-N-(4-(3,5-dimethoxystyryl) phenyl)methanesulfonamide, 4 (E)-N-(4-(3,5-dihydroxystyryl)phenyl)acetamide, 5 (E)-5-(4-
(3,5-dimethoxystyryl)phenyl)-1H–tetrazole and 6 (E)-5-(2-(3,5-dimethoxystyryl)phenyl)-1H–tetrazole. b Scheme of synthesis of compounds 3–6 (see
Methods for details). c Fluorescence determination of SIRT1 activity in vitro in the presence of 25 μM each compound, normalised against resveratrol
(1) and vehicle only control (0). Data are presented as fold change (mean ± SD) in activity normalised to enzyme-only (0) and resveratrol
(1), such that 0 represents no activation, and 1.0 indicates activation equivalent to that observed with resveratrol 1. The experiment
was carried out in 3 replicates. The numbers on the X axis (1–6) refer to the identity of each resveralogue as indicated above.
Uncertainty was calculated by subjecting the standard deviation of the control, Resveratrol and compound data to combination using
standard methods for propagation of uncertainty [49]
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SIRT1 activation is significantly altered following side
chain modification of resveratrol
Since RSV has been suggested to exert its pro-longevity ef-
fects predominantly through activation of SIRT1, we first
tested the ability of our novel compounds to activate SIRT1
in an ex vivo enzyme assay (Fig. 1c), with data normalised
against activity detected on treatment with resveratrol
(RSV, 1). While dihydroresveratrol (Fig. 1a, 2) displayed
SIRT1-activation activity equivalent to that of resveratrol,
the four novel analogues (3–6) displayed a range of activ-
ities from zero (compound 3) to around 75% of control
levels (compound 4) (Fig. 1c). These marked differences in
SIRT1 activation by the novel resveralogues (compared
with RSV and DHRSV) therefore allow us to probe SIRT1-
dependence of any biological effects.
Impact of resveralogues on the senescence-associated
secretory phenotype
We then set out to determine if treatment with resveratrol
or the novel resveralogues had an impact on the
senescence-associated secretory phenotype (SASP) in sen-
escent cultures of human fibroblasts (NHDF). The levels
of multiple cytokines including key SASP components
(IL6, IL8, TNFα, IL2, IL1β, IL-12p70, IL10, INFγ and
GMCSF) were determined in senescent NHDF by ELISA
(Fig. 2). Although each of the compounds altered cytokine
profiles to some extent (Fig. 2, see also Additional file 1:
Table S1), there was no consistent pattern with which this
occurred. Resveratrol 1 was the only compound to reduce
the levels of multiple cytokines including the key SASP
mediators IL-6 and IL-8 as well as IL2, TNFα and IFNγ,
consistent with previous reports [27]. By contrast, dihy-
droresveratrol (2) treatment significantly elevated levels of
IL-8 and several other inflammatory mediators, whilst 3–
6 had variable impact on the expression of the SASP pro-
teins assayed. The only cytokine showing a consistent
reduction in level in response to all 6 compounds was IL-
10 (Fig. 2, Additional file 1: Table S1).
Splicing factor expression and splicing patterns of
senescence-associated genes are restored in senescent
cultures of fibroblasts following treatment with
resveralogues
To establish whether RSV and the novel resveralogues
could influence splicing regulators, we first measured
splicing factor expression by qRT-PCR in senescent cul-
tures of human fibroblasts (NHDF) following 24 h treat-
ment with 5 μM of compounds 1–6. Consistent with
previous studies in HEK293 cells [22], we find that res-
veratrol (1) treatment increased levels of both splicing
activators (SRSF transcripts) and inhibitors (HNRNP
transcripts) (Fig. 3a). Importantly, novel resveratrol ana-
logues also partially restored levels of both splicing acti-
vator and inhibitor transcripts (Fig. 3a, Additional file 2:
Table S2). The level of restoration of splicing regulator
expression in treated cells was similar to levels previ-
ously reported in early passage fibroblasts [2]. This re-
versal of the age-related decline in splicing factor
expression was present for compounds with no discern-
ible SIRT activity (compound 3) as well as those that ele-
vated IL6 and IL8 levels (compounds 2 and 5),
indicating that the action of splicing factors is independ-
ent of SIRT1 and the SASP.
We then asked whether this restoration of a ‘youthful’
complement of splicing factors is biologically relevant. To
do this, we examined the alternative splicing profiles of
key genes involved in cellular senescence in senescent
NHDF cultures treated with each of the compounds
(Fig. 3b). In some cases, it was not possible to distinguish
an effect on splicing from effects on transcription, since
multiple isoforms were affected with the same directional-
ity. For example, both p14ARF and p16INK4A isoforms of
the CDKN2A gene, which increases with cellular senes-
cence [28], were down-regulated in response to treatment
with most resveralogues. However, in other cases, only
one isoform was affected; the expression of the pro-
apoptotic p21b isoform, but not the consensus isoform
p21a of the CDKN1A gene was altered, demonstrating an
effect on splicing. Similarly, increased expression of the
CHK1S isoform of the CHK1 gene, which induces mitosis
[29], but not the consensus CHK1 isoform which does
not, was seen (Additional file 2: Table S2). SIRT1 mRNA
expression was upregulated by treatment with the novel
Fig. 2 Differential effects of resveralogues on the senescence-
associated secretory phenotype (SASP). Protein levels of various
pro-inflammatory SASP factors was determined using Mesoscale
ELISA platform in culture medium of senescent HNDF cultures
treated with 5 μM resveralogues 1–6. The heat map indicates
fold changes. Con = control (vehicle only). Green indicates
up-regulation while red denotes down-regulation. The colour
scale refers to percentage change in expression. Experiments
were carried out in duplicate a total of 10 times
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resveralogues but not RSV itself. A major regulator of cell
proliferation and potential driver of senescence is mTOR:
inhibition of mTORC1 by rapamycin increases longevity
in animal models [30], while mTORC inhibition can re-
verse multiple phenotypes of cell senescence [31]. We
found elevated expression of both the mTORα and β iso-
forms, which regulate cell metabolism and cell prolifera-
tion respectively [32], on treatment with resveralogues 1–
4 (Fig. 3b, Additional file 2: Table S2), though mTORβ
was suppressed on exposure of cells to resveralogues 5
and 6. Overall, the changes in alternatively-expressed
isoforms following resveralogue treatment are consistent
with a shift towards a more proliferation-competent
repertoire.
Treatment of senescent cells with resveralogues is
associated with reduction in biomarkers of senescence
To assess whether restored splicing factor expression
was associated with rescue from cellular senescence, we
treated senescent cultures of normal human diploid fi-
broblasts from three genetically distinct cell strains
(NHDF and HF043 dermal fibroblasts and MRC5 lung
fibroblasts) for 24 h with compounds 3–6, compared
with RSV (1) and DHRSV (2) and measured transcript
levels of senescence biomarkers CD248 and CDKN2A
(encoding p16INK4/6) by quantitative reverse transcrip-
tion PCR, normalised against the IDH3B, GUSB and
PPIA endogenous control genes, which we have found
to be stable in response to senescence and ageing in our
previous work [1, 2]. Stability of control genes to resver-
alogue treatment was verified empirically. While we ob-
served differences between the cell lineages, there was
an overall significant decrease in CDKN2A and CD248
molecular markers of senescence compared with
vehicle-only control cell populations (Fig. 4a), which was
most marked for the foreskin fibroblast line HF043. To
further assess senescence, we examined levels of
senescence-associated β galactosidase (SA β-Gal). The
percentage of NHDF cells staining positive for SA β-Gal
decreased from ~75 to ~25%, compared with much
lower levels (~7%) in younger cells at PD25 (Fig. 4b),
and similar highly significant reductions in SA β-Gal re-
activity were seen in senescent cultures of MRC5 and
HF043 fibroblasts (Fig. 4b). These reductions in senes-
cence markers were still evident in NHDF cells 4 weeks
after initial treatment and larger reductions occurred fol-
lowing repeated treatments at 48 h intervals (Add-
itional file 3: Figure S1). We conclude therefore that
senescence markers are markedly diminished upon
resveralogue treatment. Given that compound 3 (which
does not activate SIRT1) has very similar effects on these
senescence biomarkers compared with resveratrol and
other resveralogues with variable SIRT-activation activity
(4, 5, 6), we can conclude that the decrease in senes-
cence biomarker expression on resveralogue treatment
can occur independently of SIRT1 activation.
Fig. 3 Splicing factor regulators are elevated following treatment with resveratrol analogues. Changes to mRNA levels in HNDF cells in response
to treatment with 5 μM resveratrol (1) or resveralogues 2–6 determined by quantitative reverse transcription PCR. a Expression of splicing factor
regulatory genes (b) Isoform-specific transcripts of genes associated with senescence and/or DNA damage responses. Con = control (vehicle
only). Green indicates up-regulated genes, red denotes down-regulated genes. The colour scale refers to fold-change in expression. Data are
derived from duplicate testing of 3 biological replicates
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Treatment of senescent cells with resveralogues is
associated with re-entry of cell cycle
While decreases in senescence biomarkers may be
beneficial in alleviating some of the detrimental ef-
fects of senescent cells, it is the loss of proliferative
capacity of senescent cell populations that is likely to
lead to stem cell exhaustion and loss of tissue func-
tion/frailty with increasing age [33]. We therefore also
assessed cell proliferation and re-entry into the prolif-
erative cell cycle. Initially, using live cell imaging of
senescent NHDF cells treated with resveratrol for up
to 92 h, we found that some cells within this popula-
tion showed clear evidence of mitosis within a little
as 17.5 h after treatment (Additional file 4: Figure
S2). We therefore assessed whether senescent popula-
tions of three different fibroblasts lines (NHDF,
MRC5 and HF043) could undergo mitosis following
treatment with the novel compounds. Remarkably,
treatment with even very low doses (5 μM) of the
resveralogues led to significant increases (up to 0.6
population doublings) in total cell numbers over only
24 h of drug exposure, while vehicle-only controls
remained proliferation-arrested (Fig. 5a). Increases in
cell number strongly suggest that a significant propor-
tion of cells in the non-cycling senescent population
have been induced to re-enter the mitotic cell cycle.
Cell proliferation kinetics are altered in treated cells
To further probe this potential induction of proliferation,
the proliferation kinetics of these cultures were deter-
mined by immunocytochemical and catalytic histochem-
ical measurement of the levels of the proliferation marker,
Ki67, and the senescence marker, SA β-Gal, respectively.
Compounds 1–6 induced a consistent increase in the
Ki67 positive fraction of cells in senescent NHDF cultures
from ~20% of nuclei to ~40%, whereas levels in younger
cells at PD25 were > 90% (Fig. 5b), consistent with the
findings of increased cell numbers and mitotic figures fol-
lowing drug administration (Fig. 5a, Additional file 4: Fig-
ure S2 and data not shown). Since the increased number
of cells staining for the proliferation marker Ki67 corre-
lates inversely with the decreased numbers staining for
SA-β gal (see Fig. 4b), we suggest that cells have exited
senescence to enter the cell cycle.
Treatment of senescent cells with resveralogues is
associated with telomere elongation
Telomere shortening is perhaps the best known trigger
of cellular senescence. Several splicing factors have been
previously demonstrated to unwind telomeres and acti-
vate telomerase and could thus potentially lengthen telo-
meres [13, 14, 34]. We therefore measured telomere
length by qPCR in NHDF cells treated with 5 μM
Fig. 4 Decreased senescence biomarkers on resveralogue treatment (a) Levels of senescence-associated transcripts CDKN2A and CD248 were assessed
in senescent populations of NHDF, MRC5 and HF043 fibroblasts by quantitative reverse transcription PCR. Data are expressed relative to stable
endogenous control genes GUSB, IDH3B and PPIA, and normalised to the levels of the individual transcripts in untreated controls (c),
1–6 = resveralogues 1–6. Fold change was calculated for in triplicate for three biological replicates (b) Senescence associated β-
galactosidase following treatment with resveralogues 1–6 was determined by manually counting the percentage of SA-β gal positive
cells (NHDF, MRC5 and HF043) in each treated or control population. n > 300 for each sample. Statistical significance is indicated by
* = p < 0.05, ** = p < 0.005, *** = p < 0.0005 (2 way ANOVA)
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resveratrol or resveralogues for 24 h, relative to telomere
length in untreated cells. We found that cells treated
with resveratrol or any of the novel resveralogues had
telomeres that were 1.3–2.4 times longer than vehicle-
only controls, compared with younger cells at PD25,
which showed telomeres 2.6 times longer than untreated
senescent cells (Fig. 5c).
Changes in splicing factor expression and senescence
markers are not effects of cell proliferation
To determine whether the changes in splicing factor ex-
pression were a cause or consequence of renewed cell
proliferation, we measured splicing factor expression
and selected senescence markers under low serum con-
ditions, which would induce proliferating cells to enter
quiescence. Unsurprisingly, serum-starved cultures dem-
onstrated no increase in cellular proliferation in re-
sponse to resveralogue treatment, as determined by lack
of an observable increase in cell numbers (Fig. 6a) or
Ki67 index (Fig. 6b) in treated cells. However effects on
both senescence markers (Fig. 6c) and splicing factor ex-
pression (Fig. 6d) were still observed, indicating that the
effects on senescence and splicing factor expression were
independent of proliferation. Uncoupling rescue from
proliferation also allows us to quantify more precisely
the percentage of cells in which senescence has been re-
versed from the dilution effect of increased cell number.
The number of ‘reverted’ cells is ~15%, which is similar
to the levels we had predicted based on the cell prolifer-
ation kinetics.
Decrease in senescent cell fraction is not due to selective
death of senescent cells
To exclude the possibility that the decrease in the per-
centage of senescent cells following treatment resulted
from selective cell death of non-proliferating cells, cyto-
toxicity was assessed using an assay for extracellular lac-
tate dehydrogenase (LDH); this intracellular enzyme is
Fig. 5 Increased proliferation of senescent cell populations following resveralogue treatment. a Cell numbers of NHDF, MRC5 and HF043
fibroblast populations following treatment with resveralogues 1–6. Experiments were carried out in triplicate for three biological replicates and
*** represents p < 0.001 (2 way ANOVA). b Proliferation index was assessed for control and treated NHDFs, as well as younger (PD25) cells as
assessed by Ki67 immunofluorescence (> 400 nuclei counted per sample, *** p < 0.001 by 2 way ANOVA). c Telomere length was quantified by
qPCR relative to the 36B4 endogenous control and normalised to telomere length in vehicle-only controls, younger passage cells (PD25) and in
cells treated with compounds 1–6. Experiments were carried out in triplicate for three biological replicates. Statistical significance is indicated by
* = p < 0.05, ** = p < 0.005, *** = p < 0.0005 (2 way ANOVA)
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only released into the culture medium upon cell death.
In all cases, cells treated with the novel compounds re-
leased lower levels of LDH than those treated with RSV
(at doses up to 100 μM) in comparison with vehicle only
controls (Additional file 5: Figure S3); compound 6 in
particular showed very low levels of LDH release. These
results demonstrate low cytotoxicity of dihydroresvera-
trol and all four novel resveralogues.
While necrotic cell death was not detected, it was im-
portant to rule out selective loss of senescent cells by
apoptosis. Levels of apoptosis in senescent NHDF cultures
treated with resveralogues 1–6 were determined by both
TUNEL and by Caspase 3 and 7 assays (Additional file 5:
Figure S3B and C). No increases in levels of apoptosis
were observed in the resveralogue-treated cultures com-
pared with vehicle-only control treatments, suggesting
that the increased proliferation on resveralogue treatment
was not a consequence of selective death of non-
proliferating cells within the population.
ERK agonists and antagonists influence cellular
senescence and splicing factor expression
ERK signalling has previously been reported to be influ-
enced by resveratrol [35, 36]. ETS-1, a transcription factor
downstream of ERK activation has also been reported to
regulate the expression of TRA2B, an important splicing
Fig. 6 Effects of resveratrol treatment in cells grown under serum starvation conditions. a Cell numbers of NHDF fibroblasts following treatment
with 5 μM resveratrol for 24 h under conditions of serum starvation. Experiments were carried out in triplicate for three biological replicates. (2
way ANOVA). b Proliferation index was assessed for NHDF fibroblasts following treatment with 5 μM resveratrol for 24 h under conditions of
serum starvation as assessed by Ki67 immunofluorescence (> 400 nuclei counted per sample). c Senescence associated β-galactosidase following
NHDF fibroblasts following treatment with 5 mM resveratrol for 24 h under conditions of serum starvation was determined by manually counting
the percentage of SA-β gal positive cells in each treated or control population. n > 300 for each sample. Statistical significance is indicated by
*** = p < 0.0005 (2 way ANOVA). d Changes to splicing factor mRNA levels in NHDF fibroblasts following treatment with 5 μM resveratrol for
24 h under conditions of serum starvation determined by qRTPCR. Control = vehicle only. Green indicates up-regulated genes, red denotes
down-regulated genes. The colour scale refers to fold-change in expression. Data are derived from duplicate testing of 3 biological replicates
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regulator [37]. To investigate the potential interplay be-
tween resveratrol and ERK signalling on splicing factor ex-
pression and cellular senescence phenotypes, we treated
senescent NHDF cells with low dose (1 μM or 10 μM) of
trametinib, a well-characterised signalling inhibitor that
inhibits the ERK signalling pathway. Treatment of senes-
cent cells with trametinib resulted in a robust decrease in
the proportion of senescent cells in the culture, which was
apparent at 1 μM and 10 μM, but not at 20 μM. Such dose
effects are not uncommon in signalling pathways due to
interconnectivity with other signalling pathways and auto-
regulation (Additional file 6: Figure S4A). Conversely,
treatment with the ERK agonist ceramide resulted in a
comparable increase in the senescent cell fraction after
24 h. Notably, the effect of ceramide was negated by the
addition of 5 μM of any of the novel resveralogues
(Additional file 6: Figure S4B). Trametinib also restored
splicing factor expression to profiles consistent with earl-
ier passage in a manner similar to that observed with the
resveralogues (Additional file 7: Figure S5).
Discussion
We have generated a panel of novel molecules based on
the small molecule resveratrol, to determine whether alter-
ation to regulators of mRNA processing could influence
cellular senescence phenotypes in human fibroblasts of dif-
ferent lineages. Treatment of senescent cultures of cells
from different genetic backgrounds with these novel mole-
cules was associated with an increase in the expression of
multiple splicing factors, to levels consistent with those
seen in early passage cells [2], although at present it is not
clear whether these are direct or indirect effects. Treatment
with all 6 resveralogues also resulted in a decline in the sen-
escent cell fraction, along with changes to the splicing pat-
terns of genes involved in cell senescence to a profile
indicative of much ‘younger’ cells. Our evidence suggests
cells have also re-entered the cell cycle, as determined by
an increase in markers of cell division with concurrent in-
creases in cell number. Finally, in accordance with the re-
ported role of some splicing factors on telomere
accessibility and telomerase activity [13–15], telomere
length was lengthened in treated cells, consistent with a ‘re-
setting’ of the telomere clock. The absence of any elevation
of either necrotic (LDH release) or apoptotic cell death
(TUNEL and caspase), also excludes the possibility that the
dramatic decline in the senescent fraction results from se-
lective killing of senescent cells by resveralogues.
Disruption to splicing factor transcript expression levels
is known to be a major feature of ageing in humans [1] and
also in senescent human primary cell lines of multiple line-
ages which have undergone in ‘ageing’ by repeated culture
in vitro [2]. Splicing factor expression is also associated with
lifespan in humans and also in mice, where their expression
appears to be early-life determinants of longevity [3].
Recent data adds weight to this hypothesis, since abolition
of the core splicing factor 1 (SFA-1) alone was to reduce
lifespan in C.elegans by interaction with the TORC1 path-
way [4]. Splicing factors are also known to be drivers of cell
proliferation [38–40], through effects both on splicing pat-
terns, and through their non-canonical roles in telomere
maintenance [13–15, 17, 34]. Telomere maintenance is crit-
ical in permitting cell proliferation; restoration of hTERTal-
lows prematurely senescing human Werner syndrome
fibroblasts to proliferate with kinetics of wild type cells [41].
Splicing factors hnRNPK and hnRNPD interact with the
hTERT promoter while knockdown of hnRNPD notably re-
duces transcription of the telomerase gene [13, 14]. Add-
itionally, hnRNPA1 is required for telomere maintenance in
multiple species and has been proposed to facilitate the ac-
cess of telomerase to the telomere [15].
The question of whether senescence drives splicing
changes, or whether splicing alterations are causative of
cell senescence in different species, tissues and points in
the life course is a challenging and multifaceted one. The
conventional approaches to answer this question are in-
tractable in this system, since there are over 100 splicing
factors involved in regulation of splicing, with exon usage
determined by the balance of activators and inhibitors at
each individual splice site [10]. The pattern and dosage of
splicing factors involved will also differ from splice site to
splice site and from tissue to tissue. There is also redun-
dancy between splicing factors, both in terms of regulation
of splicing, and also in their non-canonical roles - at least
6 hnRNPs and some SRSF proteins are known to have ef-
fects on telomere structure or telomerase activity. How-
ever, in this initial study the issue of causality can be
distilled down to whether the changes in splicing factor
expression we observe on resveralogue treatment drive
rescue from senescence or are a consequence of re-entry
into cell cycle. The observation that the alteration in spli-
cing factor expression and the decrease in numbers of
senescent cells occurs when proliferation is blocked pro-
vides evidence to suggest effects we note may lie upstream
in the causal pathway (Fig. 5).
Presently, it is not possible to attribute specific spli-
cing changes to alterations in the levels of specific
splicing factors. Splice site choice is governed by the
balance of activators and inhibitors at individual
splice sites, and the binding sites are short and de-
generate [10]. Similarly, in some cases, it is not pos-
sible to determine whether the effects on expression
we note are transcriptional or due to splicing on the
basis that expression changes of alternative isoforms
share directionality. However, for other genes, the ef-
fect is confined to specific isoforms, clearly indicating
an effect on splice site choice. Another caveat to our
work is that we have assessed expression changes at
the level of mRNA only. This is due to the inherent
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difficulty in culturing sufficient quantities of senescent
cells to allow large scale protein analysis.
At present, the specific mechanism(s) by which resvera-
logues may influence splicing factor expression and senes-
cence phenotypes in our work are not clear. Resveratrol
has previously been demonstrated to have beneficial ef-
fects on senescence phenotypes through other pathways
such as SIRT1 activity [24] and also through effects on the
senescence-associated secretory phenotype (SASP) [23].
Our data suggest that resveralogues can influence splicing
factor expression and cell division in senescent cultures
independently of SIRT1 activity, since one compound,
molecule 3 has no discernible SIRT1 activity (Fig. 1), des-
pite an induction of SIRT1 at the mRNA level. The action
of resveratrol on SIRT1 is at the level of enzyme activa-
tion. In the case of compound 3, although there appears
to be an effect on transcription, this compound is not able
to activate the translated protein. Our data are also con-
sistent with earlier studies in siRNA SIRT1 knockout cells
which demonstrated that the effect of resveratrol on spli-
cing factor expression occurs irrespective of SIRT1 activity
[22]. Similarly, although resveralogues 1–6 display very
similar effects on splicing factor expression, ability to
supress the SASP varies widely (as shown in Fig. 2). In-
deed, treatment with compound 2 significantly elevates
levels of IL-8, one of the canonical cytokines that causes
paracrine senescence (alongside IL-6). The only consistent
change to cytokine levels that we detect is a reduction in
IL-10, which is not growth suppressive.
Resveratrol has been reported to modulate the ERK path-
way [35, 36]. ERK signalling has previously been suggested
as a potential regulator of splicing factor expression [37].
Indeed, ETS1, a downstream target of ERK signalling has
previously been reported to regulate the expression of
TRA2B [37]. ERK inhibition has also been demonstrated to
suppress cellular senescence [42] and to influence lifespan
in animal models [43]. Our data are consistent with these
observations, since alterations to ERK signalling with ERK
antagonists was also associated with altered splicing factor
expression and senescence phenotypes. ERK agonists were
also able to ameliorate the effects of resveratrol on both
phenotypes. At present, however, we cannot state defini-
tively that this is the primary mode of induction of these ef-
fects, given the context and cell type dependence of ERK
signalling, and the existence of crosstalk with other path-
ways. Interpretation of data are also made more compli-
cated by the observation that even a population of
senescent cells derived from a single ‘young’ culture is actu-
ally fairly heterogeneous, consisting of deeply senescent,
newly senescent and pre-senescent cells. Within a senes-
cent cell culture, there are also several routes by which
those cells may have become senescent. These include rep-
licative senescence, mitochondrial senescence, oncogene-
induced senescence, paracrine senescence and autocrine
senescence. At the present time, it is unclear whether all
subpopulations respond to resveralogue treatment equiva-
lently, or whether cells that have become senescent via dif-
ferent routes respond equivalently to resveralogues.
There is already considerable interest in the develop-
ment of drugs that can attenuate senescence for eventual
human use. Notable successes have come from overcom-
ing apoptosis in senescence using Bcl-2 inhibitors [44],
and by modifying mTORC signalling using rapamycin and
other rapalogues or ATP mimetics specific for the mTOR
kinase active site [31]. SIRT1 is also a current target for
drug design and for nutraceutical interventions and is
known also to be activated by resveratrol. We suggest that
focusing on SIRT1 activity alone may be misleading and
that other pathways activated by resveralogues may be
more important in alleviating senescence and improving
health outcomes in later life. The renewal of proliferation
we observe upon resveralogue treatment obviously raises
questions about the potential cancer risk attached to such
treatment, should it eventually be employed in a clinical
setting. We propose that the renewed proliferation arises
from a transient increase in telomerase activity brought
about by the induction of specific splicing factor proteins,
and that the growth is still regulated. This is in accordance
with observations that treatment with resveratrol has been
suggested to have a protective effect against cancer in both
humans and rodent models [45, 46].
Conclusions
During the ageing process, both senescent and non-
senescent cells lose a degree of response to cellular
stressors. The upstream causes of this are as yet unclear,
but may include changes in genes controlling alternative
splicing; a major regulator of gene expression which en-
sures genomic plasticity. Here, we provide evidence that
treatment with novel analogues of the stilbene compound
resveratrol is associated not only with restoration of splicing
factor expression but also with amelioration of multiple cel-
lular senescence phenotypes in senescent human primary
fibroblasts. At present, the precise mechanisms behind
these observations are unclear, but may involve both the
restoration of a more ‘youthful’ pattern of alternative spli-
cing, and also effects of specific splicing factors on telomere
maintenance. We propose therefore that splicing factors,
and the upstream drivers of splicing factor expression may
prove promising as druggable targets to ameliorate ageing
phenotypes and hold promise as anti-degenerative com-
pounds effective in human cells in the future.
Methods
Synthesis of novel resveralogues
Resveratrol (Sigma Aldrich, UK; 1) was used to synthesise
dihydroresveratrol 2 as reported previously [47]. (E)-N-(4-
(3,5-Dimethoxystyryl)phenyl) methanesulfonamide 3 was
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synthesised from the previously reported nitro-substituted
analogue 7 via an Fe/NH4Cl reduction to give amine 8 [26],
followed by sulfonylation with methanesulfonyl chloride
(Fig. 1b). The corresponding amide 9 was also prepared
from 8, by acylation with acetylchloride. The product 9 was
subjected to demethylation (BBr3, CH2Cl2) to give the target
compound (E)-N-(4-(3,5-dihydroxystyryl)phenyl)acetamide
4. (E)-5-(4-(3,5-dimethoxystyryl)phenyl)-1H–tetrazole 5 and
the isomeric 2-1H-tetrazole analogue 6 were prepared dir-
ectly via acid-catalysed cycloaddition with azide ion from
the 4- and 2-cyanostilbenes [26] (10 and 11 respectively).
(Fig. 1b) Details of the synthesis, purification and character-
isation of the resveralogues are given in Additional file 8.
Determination of SIRT1 enzyme activation
SIRT1 enzyme activity was measured by using the SIRT1
Fluorometric drug discovery kit (Cayman Chemicals, Mich-
igan, USA) according to the manufacturer’s instructions.
This assay is a standard direct fluorescent screening assay
for SIRT1 ex-vivo and is essentially a variant of the well-
known “fluor de lys” system. For determination of the rela-
tive capacity of each resveralogue to activate the enzyme,
25 μM solution of each compound (n = 3) was preincu-
bated with the enzyme and co-factors before measurement
of activity. Quantification was achieved by measuring out-
put at λex = 360 nm and λem = 460 nm. Each plate included
background measurements and enzyme-only controls. Data
are presented as fold change (mean ± sd) in activity nor-
malised to enzyme-only and resveratrol 1, such that 0 rep-
resents no activation, and 1.0 indicates activation equivalent
to that observed with resveratrol 1.
Determination of cytotoxicity of resveralogue library
A commercial LDH release assay (Pierce LDH Cytotox-
icity Assay Kit) was used to determine cell death. Briefly,
MRC5 cells (at population doubling (PD) = 45) were
seeded in 24 well plates at 1.3 × 105 cells/cm2 and allowed
to recover from trypsinisation for 24 h then exposed to
each of the resveralogues (3 biological replicates × 3 con-
centrations; 10, 50 and 100 μM) for a further 24 h. 50 μl
of media from each well was then mixed with an equal
volume of LDH assay reaction mixture and incubated at
room temperature in the dark for 30 min. 50 μl of LDH
assay stop solution was added to each well and the absorb-
ance of the solution was measured by spectrophotometry
at 490 nm. Complete lysis and vehicle only positive and
negative controls were included. Data are presented as
mean (+/−standard deviation) % of the total lysis control.
Culture of human primary fibroblasts (NHDF, MRC-5 and
HF043)
Fibroblast cell strains of three genetic backgrounds and
two lineages were used in this study: normal human der-
mal fibroblasts (NHDF; Heidelburg, Germany), human
diploid foetal lung fibroblasts (MRC-5; Coriell Institute
for Medical Research) and neonatal foreskin fibroblasts
(HF043; Dundee Cell Products, UK). Standard culture
conditions were a seeding density of 6 × 104 cells/cm2 in
media (C-23020, Promocell, Heidelburg, Germany) con-
taining 1% penicillin and streptomycin, and a fibroblast-
specific supplement mix consisting of foetal calf serum
(3% v/v), recombinant fibroblast growth factor (1 ng/ml)
and recombinant human insulin (5 μg/ml) (Promocell,
Heidelburg, Germany). For the assays requiring senes-
cent cultures, cells were counted and equal numbers of
cells seeded at each passage until the growth of the cul-
ture slowed to less than 0.5 PD/week as previously de-
scribed [2] (this occurred at PD = 64 (NHDF), 65
(MRC-5) and 64 (HF043). Viable cell numbers were de-
termined at each passage by trypan blue staining. For
cultures grown under serum starvation conditions, cells
were maintained in DMEM (Sigma Aldrich, Dorset, UK)
supplemented with 0.1% of serum and 1% penicillin and
streptomycin in the absence of fibroblast-specific supple-
ment, for 24 h prior to treatment.
Quantification of secretion of key cytokines
NHDF cells from a senescent culture were seeded at
6 × 104 cells/cm2 in a 6 well plate in serum-free media,
and after 10 days were treated with 5 μM of each of 1–6
for 24 h. Cell supernatants were then harvested and
stored at −80 °C. Levels of 9 cytokines (GMCSF, IFNγ,
IL1β, IL2, IL6, IL8, IL10, IL-12p70, and TNFα) in cell
supernatants from treated and vehicle-only control cells
were determined using the K15007B MesoScale Discov-
ery multiplex ELISA immunoassay (MSD, Rockville,
USA) in 11 replicates. Proteins were quantified relative
to a standard curve using a Sector Imager SI-6000 ac-
cording to the manufacturer’s instructions. Data are pre-
sented as mean (+/−SEM).
Expression profiling of splicing factor expression in
cultures of senescent cells
NHDF cells were seeded at 6 × 104 cells/cm2 in 6 well
plates, allowed to grow for 10 days then treated with 5 μM
of each compound for 24 h in 3 biological replicates, with
vehicle only controls (DMSO). Resveratrol 1 acute treat-
ment was at an initial dose of 5 μM, followed by culture
without further treatment for 4 weeks. For chronic treat-
ment regimes, resveratrol (or DMSO vehicle) was added
once every 48 h during 4 weeks. 20 splicing factor tran-
scripts that associated with age and replicative senescence
in our previous work [1, 2] were selected a priori for assess-
ment here. (Assay identifiers are available on request). RNA
was extracted by using 1 ml of TRI reagent ® (Life Tech-
nologies, Foster City USA) according to the manufacturer’s
instructions. Total RNA (100 ng) was reverse transcribed in
20 μl reactions using the Superscript III VILO kit (Life
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Technologies, Foster City, USA). Transcript expression was
then quantified in triplicate for each biological replicate
using TaqMan Low Density Array (TLDA) on the ABI-
Prism 7900HT platform. Cycling conditions were 1 cycle
each of 50 °C for 2 min, 94.5 °C for 10 min and then 40 cy-
cles of 97 °C for 30 s and 57.9 °C for 1 min. The reaction
mixes included 50 μl TaqMan Fast Universal PCR Master-
mix (Life Technologies, Foster City, USA), 30 μl dH2O and
20 μl cDNA template. 100 μl reaction mixture was dis-
pensed into the TLDA card chamber and centrifuged twice
for 1 min at 1000 rpm to ensure correct distribution of so-
lution to each well. Transcript expression was assessed by
the Comparative Ct approach, relative to the IDH3B, GUSB
and PPIA endogenous control genes, selected on the basis
of empirical evidence for stability with age in our earlier
microarray data [1] and with cellular senescence in our
earlier work [2]. Transcript expression was expressed rela-
tive to the level of splicing factor expression in vehicle
treated control cells.
Assessment of total gene expression and alternative
splicing for senescence-related genes
To assess gene expression and splicing, NHDF cells were
seeded at 6 × 104 cells/cm2 in 6 well plates and after
10 days were treated with 5 μM of each compound for
24 h in 3 biological replicates. Target transcripts included
the known age-related genes CDKN2A, CDKN1A, TP53,
MTOR, CHK1 and CHK2. Probes specific to particular
isoforms or groups of isoforms were designed to unique
regions of the transcripts in question. Assays were vali-
dated by standard curve analysis of 7 serial 1:2 dilutions of
pooled cDNA and proved robust and sensitive with an
average efficiency of −3.4 and an average r2 for reproduci-
bility between replicates of 0.87. PCR reactions contained
2.5 μl TaqMan Universal Mastermix (no AMPerase) (Ap-
plied Biosystems, Foster City, USA), 0.9 μM each primer,
0.25 μM probe and 0.5 μl cDNA reverse transcribed as
above in a total volume of 5 μl in a 384 well plate. PCR
conditions were a single cycle of 95 °C for 10 min followed
by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. We also
measured the total expression of the ATR, ATM. RB1,
SIRT1 and SIRT2 genes. Probe and primer details are
available on request. Each biological replicate was tested
in triplicate. Isoform-specific and total expression changes
were examined for statistical significance by two way
ANOVA analysis using SPSS v.22 (IBM, USA).
Catalytic histochemical determination of SA β-gal positive
fraction
Senescence marker SA β-Gal was assayed in triplicate
using a commercial kit (Sigma Aldrich, UK); according
to manufacturer’s instructions, with a minimum of 400
cells assessed per replicate.
qRTPCR measurement of transcripts of senescence
associated genes
Molecular markers of senescence (CDKN2A and CD248
transcript levels) were measured by qRTPCR relative to
the GUSB and PPIA endogenous control genes, on the
ABI Prism 7900HT platform. PCR conditions and ana-
lysis were as previously described [2].
Live cell capture microscopy
For live capture microscopy, cells were seeded at a dens-
ity of 5 × 104 cells per 35 mm glass bottomed dish
(World Precision Instruments, USA) in 2 ml of media.
They were then imaged on a Leica Axiovert inverted en-
vironmental microscope with heated chamber (37 °C)
and CO2 capabilities. An image was taken every 10 min
over the course of 92 h. A 20× objective was used with a
30 mS shutter speed and 10% light intensity from a
widefield white light source for each image giving opti-
mal contrast and minimal light exposure. Images were
analysed using Leica LAS X software.
Determination of cell proliferation
Senescent cultures of each strain were seeded at
6 × 104 cells/cm2 into 6-well plates and cultured for
10 days then treated with 5 μM of each compound
for 24 h. Cell counts in three replicates of treated
and vehicle-only cultures were carried out manually
following trypsinisation and suspension of cells and
are presented as mean (+/−SEM).
Immunocytochemical determination of Ki67 positive
fraction
Proliferation index was assessed by using Ki67 staining
on NHDF cells. Cells were seeded at 1 × 104 cells/cover-
slip and after 10 days were treated with 5 μM of each
compound for 24 h in 3 biological replicates. Cells were
fixed for 10 min with 4% PFA and permeabilized with
0.025% Triton and 10% serum in PBS for 1 h. Cells were
then incubated with a rabbit monoclonal anti-Ki67 anti-
body (ab16667, Abcam, UK) at 1:200 overnight at 4 °C
followed by FITC-conjugated secondary goat anti-rabbit
(1:400) for 1 h, and nuclei were counterstained with
DAPI. Coverslips were mounted on slides in DAKO
fluorescence mounting medium (S3023; Dako). The pro-
liferation index was determined by counting the percent-
age of Ki67 positive cells from at least 400 nuclei from
each biological replicate at 400× magnification under a
Leica D4000 fluorescence microscope.
Assessment of apoptosis using TUNEL assay
Terminal DNA breakpoints in situ 3 - hydroxy end la-
beling (TUNEL) was to quantify levels of apoptosis in
NHDF cells. Cells were seeded at 1 × 104 cells/cm2 in 6
well plates and after 10 days were treated with 5 μM of
Latorre et al. BMC Cell Biology  (2017) 18:31 Page 12 of 15
each compound for 24 h in 3 biological replicates. The
TUNEL assay was performed with Click-iT® TUNEL
Alexa Fluor® 488 Imaging Assay kit (Thermofisher, UK)
following the manufacturer’s instructions. Negative and
positive (DNase1) controls were also performed. The
apoptotic index was determined by counting the per-
centage of positive cells from at least 400 nuclei from
each biological replicate at 400× magnification.
Assessment of apoptosis by assessment of Caspase 3 and
7 activity
Caspase-3 and-7 activities were assessed as secondary
measures of apoptosis. Cells were seeded (1000 cells per
well) in a white-walled 96-well plate and then treated with
5 μM of each compound for 24 h in 11 biological repli-
cates alongside vehicle-only controls. Caspase-3 and -7 ac-
tivities in the supernatants were then measured by
Caspase-Glo 3/7 assay (Promega, Madison, WI, USA) fol-
lowing the manufacturer’s instructions. Luminescence was
measured by using a BMG Pherastar FSX.
Moderation of ERK signalling pathway with inhibitors and
agonists
The role of ERK signalling in reversal of senescence was in-
vestigated using agonists (ceramide) and inhibitors (trameti-
nib) of the ERK pathway. Cells from a senescent culture
were seeded at 6 × 104 cells/cm2 in a 6 well plate in serum
free media, and after 10 days were treated with 1-20 μM of
the ERK inhibitor trametinib (LC laboratories, Woburn,
USA for 24 h hours, or with the ERK agonist N-Acetyl-D-
sphingosine (C2-ceramide; Sigma Aldrich, UK) at 20 μM for
24 or 120 h. To examine the role of ERK signalling in
resveralogue-induced rescue of senescence, HNDF cells
were treated with 20 μM of the ERK agonist C2-ceramide as
above, but with the addition of 5 μM resveralogue for 24 h.
Assessment of telomere length in resveratrol treated cells
DNA was extracted from 2 × 105 NHDF cells treated
with 5 μM resveralogue for 24 h, using the PureLink®
Genomic DNA Mini Kit (Invitrogen™/Thermo Fisher,
MA, USA) according to the manufacturer’s instructions.
DNA quality and concentration was checked by Nano-
drop spectrophotometry (NanoDrop/Thermo Fisher,
MA, USA). Relative telomere length was assessed by a
modified qPCR protocol [48]. PCR reactions contained
1 μl EvaGreen (Solis Biodyne, Tartu, Estonia), 2 μM each
primer and 25 ng DNA in a total volume of 5 μl in a
384 well plate. PCR conditions were a single cycle of
95 °C for 15 min followed by 45 cycles of 95 °C for 10 s,
60 °C for 30 s and 72 °C for 1 min. Telomere length was
calculated using the comparative Ct approach relative to
the 36B4 housekeeping gene and normalised to the
quantification from untreated cells. Three biological rep-
licates were tested and each was assessed in triplicate.
Statistical analysis
Unless otherwise indicated, differences between treated and
vehicle-only control cultures were assessed for statistical
significance by two way ANOVA analysis using SPSS v.22
(IBM, USA).
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